

Pressrelease

Zenicor signs agreement with provider in NHS England

Stockholm September 24th, 2019

Zenicor has signed an agreement with a primary care provider in the English National Health Service (NHS) regarding the introduction of a more efficient care pathway with Zenicor-ECG for the investigation of patients with heart palpitations. The agreement with the NHS applies to five clinical centres within Bradford CCG (Clinical Commissioning Group), commencing October 2019. Fully developed, the agreement with Bradford CCG is estimated to generate a revenue of £ 80,000 per year. Within NHS England, there are a total of 191 CCGs.

The agreement provides more patient-centred care for patients with palpitations or other arrhythmia symptoms. The design of the care pathway enables start of investigation at the patient's first visit to the primary care provider. The new care pathway is in line with NHS's overall goal to create more efficient and patient-centred care without straining healthcare resources.

The model for the more efficient care pathway is developed by Zenicor together with healthcare providers in Finland and in Sweden and has now been adapted and implemented in the NHS.

- There is a great potential to improve care for patient experiencing palpitation in primary care as the current care pathway involve long waiting times for specialist referral and poor utilization of resources. We're using the Zenicor-ECG as it is well adapted to the centralized interpretation model and enables scaling in a primary care setting, says Matthew Fay, Clinical Chief Executive and GP Principal, The Willows Medical Practice, Bradford CCG

- We are very pleased that NHS England chooses to implement an improved care pathway for early diagnosis of arrhythmias with the help of Zenicor-ECG. The agreement shows that our model also fits the healthcare system in England and we see the agreement as the starting point for the distribution of the new effective care pathway in the NHS throughout England, says Mats Palerius, CEO, Zenicor Medical Systems AB.

About Zenicor

Zenicor Medical Systems is a Swedish medical technology company developing solutions for early arrhythmias detection and stroke prevention with over 15 years' experience. The Zenicor solution consists of a handheld, lead I ECG device and a web-based system for analysing and processing the ECG data. The solution is currently in use in over 400 clinics and 10 countries in Europe. Zenicor has always worked in close cooperation with the healthcare, which has enabled an integrated specialist and primary care solution with a clear patient focus resulting in the improved arrhythmia care pathway where the healthcare resources can be used more efficiently. Zenicor's solution has been used in the major screening studies STROKESTOP I and II and now also in the world's largest randomized screening study SAFER in the UK. For more information, visit: www.zenicor.com

About NHS England

NHS England, the world's largest healthcare provider, provides England's approximately 55 million people with health care. NHS England is divided into 191 so-called CCG (Clinical Commissioning Groups) each responsible for health care in a specific geographical area. Primary care in England, which is part of NHS England and CCG's responsibility, consists of about 7,000 GPs (GP practices). For more information, visit: www.england.nhs.uk

For further information, please contact:

Mats Palerius, CEO, Zenicor Medical Systems AB

Phone: +46 70 561 55 64

Email: mats.palerius@zenicor.se

High resolution images of Zenicor-ECG is available for download: <https://zenicor.com/press-material/>

This press release consists of inside information that Zenicor is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the above-mentioned contact person's IR-agency at the 24th of September, 2019.